Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Name:
PIIS1470204517303182.pdf
Size:
486.2Kb
Format:
PDF
Description:
Open access full text article
Authors
Faivre-Finn, CorinneSnee, M
Ashcroft, Linda
Appel, W
Barlesi, F
Bhatnagar, A
Bezjak, A
Cardenal, F
Fournel, P
Harden, S
Le Pechoux, C
McMenemin, R
Mohammed, N
O'Brien, M
Pantarotto, J
Surmont, V
Van Meerbeeck, J
Woll, P
Lorigan, Paul C
Blackhall, Fiona H
Affiliation
Division of Molecular and Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, ManchesterIssue Date
2017-06-19
Metadata
Show full item recordAbstract
Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy treatment regimen in limited-stage small-cell lung cancer.Citation
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. 2017 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(17)30318-2PubMed ID
28642008Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(17)30318-2